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Abstract: Rheumatoid arthritis (RA) is an inflammatory autoimmune condition typified by 
systemic inflammation targeted toward synovial joints. Inhibition of proinflammatory networks 
by disease-modifying antirheumatic drugs, eg, methotrexate and biologic therapies, including 
tumor necrosis factor-α inhibitors, often leads to suppression of disease activity observed at 
the clinical level. However, despite the era of widespread use of disease-modifying treatments, 
there remain significant groups of patients who continue to experience pain. Our study formu-
lated a pain assessment tool in the arthritis clinic to assess feasibility of measurements includ-
ing the visual analog scale (VAS) and painDETECT to assess multimodal features of pain in 
people with established RA (n=100). Clinical measures of disease activity (Disease Activity 
Score in 28 Joints [DAS28]) were also recorded. Our data showed that despite the majority of 
subjects on at least one disease-modifying agent, the majority of patients reported severe pain 
(54%) by VAS, despite well-controlled clinical disease, with mean DAS28 2.07±0.9. Using 
the painDETECT questionnaire, 67% of patients had unlikely neuropathic pain. A significant 
proportion of subjects (28%) had possible neuropathic pain and 5% had features of likely 
neuropathic pain by painDETECT scoring. We found a positive correlation between VAS and 
painDETECT (R2=0.757). Of note, the group who had likely or probable neuropathic pain also 
showed significantly increased pain reporting by VAS (P,0.01). Subjects who were clinically 
obese (body mass index .30) also had statistically higher proportions of pain reporting (VAS 
89.0±0.7 mm) compared with subjects who had a normal body mass index (VAS 45.2±21.8 mm), 
P,0.05. Our findings suggest that multimodal features of pain perception exist in RA, including 
neuropathic and sensitization elements, perhaps explaining why a subgroup of people with RA 
continue to experience ongoing pain, despite their apparent suppression of inflammation.
Keywords: rheumatoid arthritis, pain, sensitization, painDETECT, neuropathic pain
Introduction
Rheumatoid arthritis (RA) is an archetypal autoimmune-mediated proinflamma-
tory condition. Clinically, it is typified by swelling, pain, and reduced function in 
affected joints. Uncontrolled RA causes disability and reduces quality of life, placing 
a high disease burden on affected populations.1 Disease-modifying antirheumatic 
drugs (DMARDs) and biologic drugs, including tumour necrosis factor inhibitors, 
can reduce disease activity and improve disability. However, despite a host of new 
immune-mediated therapies available to treat RA, significant numbers of patients 
exist who continue to experience pain, despite the use of DMARDs.2 The UK-based 
National Institute for Health and Care Excellence (NICE) guidance has outlined best 
practice,1 and several international guidelines for RA care exist to guide treatment.3 
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Current interventions achieve remission in 30% of patients 
but leave many, ie, 50%–60%, with ongoing disease activity 
in the UK alone.4
An increasing challenge in RA management is to opti-
mize disease remission and treatment of pain in a significant 
number of patients who report ongoing pain despite treat-
ment with often expensive disease-modifying drugs. In a 
recent UK-based study of 1,189 people with RA, after 1 year 
of treatment with disease-modifying drugs, the level of pain 
reporting remained high.5 McWilliams et al5 showed that 
there was no significant change in reported pain levels despite 
the use of disease-modifying drugs. Such observations, now 
also from other groups,6,7 have led to the formulation of 
the hypothesis that people with RA have a heightened pain 
experience very early on in their disease. It is possible that 
people with early RA may have multiple components of 
pain, including neuropathic and sensitization elements. By 
sensitization we mean a process of heightened pain percep-
tion derived from hypersensitivity to stimuli by sustained 
activation of peripheral nociceptors, eg, in the arthritic joint.8,9 
Merskey8 defined pain as “an emotional experience with an 
unpleasant sensation that is accompanied by an actual or 
potential damage or injury to tissue.” It is fundamentally one 
of the most impairing symptoms among people with RA. Pain 
is a persisting symptom in people with RA, and up to ∼70% 
would like to see improvements in pain compared with other 
symptoms of RA.2,10,11
In this article, we propose methods by which pain assess-
ment in the clinic can assist to establish the nature of pain 
phenotypes in RA. A number of groups have recently reported 
the use of the painDETECT questionnaire12 as a quantitative 
tool for measuring noninflammatory, neuropathic, or sensi-
tization elements of pain. The painDETECT questionnaire 
has already been investigated in distinct groups of people 
with musculoskeletal pain, including fibromyalgia,13 back 
pain,14 and osteoarthritis.15 All of the studies described have 
reported neuropathic/sensitization features of pain in the mus-
culoskeletal conditions described, including in people who 
were already being treated with analgesic drugs. However, 
to our knowledge, no reports on the use of the painDETECT 
questionnaire in pain reporting in RA have been published 
to date. We used the published version of the painDETECT 
questionnaire, which was developed by Freynhagen et al,12 
and used it for the first time in people with RA to assess pain 
characteristics in this autoimmune condition. Our work has 
found that RA pain is likely to be a multimodal entity with 
features of inflammation, neuropathic pain, and  sensitization. 
We propose that wider use of painDETECT in the clinical 
setting of arthritis clinics may assist in identifying neuro-
pathic or sensitization pain features in people with RA to 
help optimize their future pain management.
Methods
We conducted a study of 100 participants (32 males and 
68 females) with confirmed RA based on American College 
of Rheumatology/European League Against Rheumatism 
criteria3 from a tertiary care rheumatology center at St George’s 
Hospital, London, UK. A patient reporting tool was formulated, 
consisting of 24 questions, and was used to evaluate the effec-
tiveness of pain management and  monitoring. Pain analysis 
tools, including the visual analog scale (VAS) (0–100 mm) and 
the painDETECT  questionnaire, were included to evaluate pain 
intensity, duration, and nature in the group. Additional demo-
graphic data and Disease Activity Score in 28 Joints (DAS28) 
for RA duration, use of DMARDs, and demographic data were 
also collected. The data collection tools used in this study are 
summarized in Table 1. Full ethical approval for this study 
was provided by the London Surrey Borders Ethics Committee 
(REC No 115212). Participants were interviewed during their 
routine clinic appointment and identified from arthritis clinic 
records. They were eligible to participate in the study if their 
treatment had been stable for the previous 3 months and they 
did not require corticosteroid therapy.
The VAS is a widely used tool in pain assessment for RA 
and forms part of the pain reporting tool in DAS28.16,17 To date, 
additional tools such as the painDETECT questionnaire, which 
is now increasingly used to assess neuropathic elements of 
pain, have not been reported widely in assessments of people 
with RA. To investigate the value of pain assessment tools in 
addition to VAS, we explored the use of the painDETECT 
questionnaire in a group of people with established RA. We 
set parameters for VAS and painDETECT based on published 
reporting for subsets of pain. Previous studies have described 
Table 1 Stratification of patients based on pain questionnaires 
and disease activity indices
Scoring system Range Interpretation
Visual analog scale 0–30 Mild pain
31–53 Moderate pain
54–100 Severe pain
painDETECT #12 Unlikely neuropathic pain
13–18 Possible neuropathic pain
19 Likely neuropathic pain
Disease Activity Score  
in 28 Joints
#3.2 Low disease activity
3.3–5.1 Moderate disease activity
.5.1 High disease activity
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VAS measurements for pain as mild (0–30 mm), moderate 
(31–53 mm), and severe (54–100 mm).18 With respect to pain-
DETECT, scores suggesting likely neuropathic pain are 19, 
probable neuropathic pain 13–18, and unlikely neuropathic 
pain #12. The painDETECT questionnaire was validated and 
developed in Germany.12 It is a patient-based questionnaire 
that could be used by specialists as well as nonspecialists. It 
consists of nine items of which seven are weighted sensory 
descriptor items and two items relate to the spatial (radiating) 
and temporal characteristics of the individual pain pattern. 
From the answers, an overall score is generated ranging from 
1 to 38. According to the researchers who developed the 
painDETECT questionnaire,12 a score of #12 indicates that 
a neuropathic component is unlikely (with a true negative 
sensitivity of ,15%), a score of 19 suggests that the pain 
is likely to have a neuropathic component (with a true posi-
tive sensitivity of .90%), and a score of 13–18 indicates that 
there is a slight chance that there is a neuropathic component. 
This tool for assessing neuropathic pain when compared with 
clinical diagnosis has 85% sensitivity and 80% specificity.12
Pain reporting data were also compared with recorded 
DAS28 scores in our patient group. The simplified DAS28 
is a modified derivative of the original DAS, assessing 
28 designated joints from the 44 joints in original reports.19,20 
This tool is generally used by the physician or specialist nurse 
to assess the number of swollen and tender joints out of the 28. 
It also takes account of the erythrocyte sedimentation rate 
(ESR) or the C-reactive protein (CRP). The ESR and CRP 
can both be used to measure the degree of inflammation in the 
serum, with usually one of the readings, either ESR or CRP, 
being used to calculate the DAS28 for the patient according 
to the formula given here. The patient’s global assessment of 
health on a 0–100 scale is also measured. In addition, the VAS 
component of the DAS28 is usually the only pain assessment 
tool used in many clinical settings for RA care. Once the 
scores are calculated, they are then used in a mathematical 
formula to produce the overall disease activity score:
DAS =  0.56×√TJC + 0.28×√SJC + 0.70×ln(ESR)  
+ 0.014×GH
where TJC = tender joint count, SJC = swollen joint count, 
ESR = erythrocyte sedimentation rate, and GH = general 
health.
Values of DAS28 .5.1 indicate high disease activity, 
3.2–5.1 means moderate disease activity, 2.6–3.2 means 
low disease activity, and a score of ,2.6 means the patient 
is in remission.21
Statistical analysis
All data were analyzed using GraphPad Prism 7 software. 
Continuous data were described and analyzed using para-
metric statistics. Variables following a normal distribution 
were assessed as mean ± standard deviation. When com-
paring three or more groups, one-way analysis of variance 
was used. Nonparametric data were presented as descrip-
tive statistics (median, interquartile range) and analyzed 
using the chi-square test. The categorical variables were 
recorded as numbers (n) and percentages (%) and were 
compared using the chi-square test if they had three or 
more categories. Statistical significance was considered 
at P-values ,0.05.
Results
The results from our study demonstrate that participants 
with RA reported relatively high pain levels, despite the 
widespread use of disease-modifying drugs in this group 
of patients (Tables 2 and 3). The majority of participants 
with RA, namely 54%, reported “severe pain” on the VAS, 
which identifies people with a VAS of 54–100 mm as having 
the highest severity of pain. The mean DAS28 in the group 
was 2.07±0.9. The majority of subjects had a duration of 
diagnosis 5 years (84%). All participants evaluated had 
been stable on DMARD therapy for at least 3 months prior 
to completing the study and had not required a change in 
their treatment or addition of corticosteroid therapy during 
that time. The majority of participants were being treated 
with disease-modifying drugs, including the commonest 
agent, methotrexate (82%). Table 2 shows a summary of 
the DMARD agents being taken by the group as a whole, 
with the majority being on methotrexate and combination 
therapy in the form of additional oral DMARDs, eg, metho-
trexate, sulfasalazine, hydroxychloroquine, penicillamine, 
or ciclosporin. Additionally, all the subjects who were on 
biologic drugs and therefore by definition had more severe 
disease reported pain in the “severe pain” group. That is, of 
39 participants who were taking one of the biologic agents 
infliximab, abatacept, or tocilizumab, 76.9% reported 
“severe pain”. Our data suggest that initial treatment 
may not have been efficient in achieving disease control 
measured by DAS28 score, leading to the decision to use 
combination DMARD therapy. The use of pain-relieving 
medications was also greatest in the “severe pain” group, 
which had the highest use of analgesic medications includ-
ing paracetamol, ibuprofen, and other pain-relieving agents. 
The painDETECT questionnaire was used to evaluate for a 
possible neuropathic element of pain among the RA group. 
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Table 2 Demographic characteristics for participants with rheumatoid arthritis and their use of disease-modifying drugsa
All  
(N=100)
VAS P-value
Mild pain  
(N=19)
Moderate pain  
(N=27)
Severe pain  
(N=54)
DMARDs 0.093 χ²
 Methotrexate 82 10 22 50
 Sulfasalazine 31 9 8 14
 Hydroxychloroquine 38 8 15 15
 Penicillamine 8 0 2 6
 Ciclosporin 13 0 3 10
Biologics 0.043 χ²
 Infliximab 20 0 1 19
 Abatacept 17 1 7 9
 Tocilizumab 2 0 0 2
Pain medication 0.393 χ²
 Paracetamol 79 14 20 45
 Ibuprofen 26 4 9 13
 Other 48 9 7 32
painDETECT 8.77±5.58 2.84±1.30 5.00±1.96 12.74±4.46 ,0.0001 F
DAS28 2.09±0.96 1.95±1.08 2.16±0.86 2.16±0.86
Notes: aContinuous data are presented as M ± SD and categorical data are presented as n (%). One-way ANOVA (F) was used to determine the significant difference 
between the three groups (mild, moderate, and severe pain) for the parametric data. Categorical data were analysed using the chi-square test (χ²). painDETECT one-way 
ANOVA: (F[2, 97]=349.6, P,0.0001). The post hoc comparison for painDETECT using the Tukey test indicated that the significant difference is between all the conditions: 
mild vs moderate (M =-32.83, SD =1.947), mild vs severe (M =-60.54, SD =2.312), and moderate vs severe (M =-27.71, SD =2.099).
Abbreviations: VAS, visual analog scale; DMARDs, disease-modifying antirheumatic drugs; DAS28, Disease Activity Score in 28 Joints; M, mean; SD, standard deviation; 
ANOVA, analysis of variance.
Table 3 Characteristics for age, body mass index, sex, smoking history, and duration of diagnosis for rheumatoid arthritis 
study groupa
All (N=100) VAS P-value
Mild pain  
(N=19)
Moderate pain  
(N=27)
Severe pain  
(N=54)
Age, years 0.358 χ²
  #30 7 1 3 3
  31–40 15 5 4 6
  41–50 52 12 12 28
  51–60 20 1 7 12
  61–70 6 0 1 5
BMI 24.31±2.31 23.45±1.31 23.78±1.68 24.88±2.69 0.0231 F
Sex 0.833 χ²
  Male 32 7 9 16
  Female 68 12 18 38
Smoking history
  Yes 10 1 1 8 0.253 χ²
  No 90 18 26 46 0.858 χ²
Duration of RA 0.977 χ²
  2–4 years 16 3 4 9
  5 years 84 16 23 45
Notes: aContinuous data are presented as M ± SD and categorical data are presented as n (%). One-way ANOVA was used to determine the significant difference between 
the three groups (mild, moderate, and severe pain) for the parametric data. Categorical data were analyzed using the chi-square test (χ²). BMI one-way ANOVA: (F[2, 97]=3.919, 
P=0.0231). The post hoc comparison for the BMI using the Tukey test indicated that the statistical difference is between the mild and the severe (M =-1.432, SD =0.5981). 
However, there was no statistical difference between mild vs moderate (M =-0.3267, SD =0.6715) and between moderate vs severe (M =-1.106, SD =0.5285).
Abbreviations: VAS, visual analog scale; BMI, body mass index; RA, rheumatoid arthritis; M, mean; SD, standard deviation; ANOVA, analysis of variance.
Figure 1 shows that 33% of participants reported possible 
or likely neuropathic pain by painDETECT. Additionally, 
there was a clear positive trend between VAS scores and 
painDETECT scores, suggesting that the high level of pain 
reported on the VAS also correlated with high  neuropathic 
pain scores (R2=0.757). One of the components of the 
painDETECT questionnaire is the body map, where subjects 
can mark body areas in which they felt pain. The majority 
of participants with probable neuropathic pain or likely 
neuropathic pain reported pain around their knees, ankles, 
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thighs, lower back, wrists, and shoulders on body mapping, 
suggesting widespread pain in keeping with likely sensitiza-
tion in our RA group.
Analysis of sex differences in pain reporting did not 
identify any significant differences between men and women 
(Figure 2). When asked about their current pain compared 
with worst ever pain in their joints, a significant number of 
participants reported an improvement in their pain reporting 
at current levels (Figure 2B), suggesting that the majority of 
 subjects had experienced higher pain levels previously. We 
also assessed the group for evidence of obesity by body mass 
index (BMI), since higher levels of obesity are known to corre-
late with higher pain reporting.22 We found that the reporting of 
pain by VAS increased according to subgroupings for subjects 
who were overweight and obese (Figure 3). The differences 
between the “normal” BMI group and the overweight or obese 
BMI group were statistically significant (P,0.05).
When participants were grouped according to those 
on oral DMARDs alone (ie, methotrexate, sulfasalazine, 
 hydroxychloroquine, penicillamine), biologic drugs, and 
DMARDs (ie, methotrexate and infliximab or tocilizumab 
or abatacept), the mean VAS for the oral DMARD group 
was 52.0±21.3 mm (Figure 4A). For the biologic and 
oral DMARD group, the mean VAS was 68.2±18.5 mm, 
suggesting that participants on combination oral and bio-
logic DMARD therapies had the highest VAS pain scores 
reported compared with participants not on any DMARD 
therapy (P#0.0001). In comparison, 14% of the total group 
were not on any DMARD therapy, with a mean VAS of 
30.4±19.5 mm. The results of the painDETECT question-
naire divided subjects into three groups: unlikely neuropathic 
pain, possible neuropathic pain, and likely neuropathic 
pain. We found that the likely neuropathic pain group also 
reported the highest pain levels on VAS, with a mean VAS 
of 90.1±4.3 mm (Figure 4B), which was statistically sig-
nificant compared with the unlikely neuropathic pain group 
(P#0.01).  Interestingly, participants in the possible neuro-
pathic pain group also demonstrated high VAS reporting, 
Pain scoring parameter Value
Visual analog scale (VAS) for pain
0–30
A
B
Mild pain
31–53 Moderate pain
54–100
≤12 Unlikely neuropathic pain (UNP)
≥19
120
Likely neuropathic pain (LNP)
13–18 Possible neuropathic pain (PNP)
Severe pain
19.1±6.2
Mean ± SD
45.6±6.7
72.8±12.8
N=
67
28
5
painDETECT
100
80
60
V
A
S
 (
m
m
)
40
20
0
0 5 10 15 2520
y=3.6584x + 23.166
R2 =0.7568
painDETECT score
Figure 1 (A) Table showing categorization of rheumatoid arthritis group by pain stratification using visual analog scale (VAS) and painDETECT questionnaires. The numbers 
(N) represent number of participants in the study with the scoring for unlikely neuropathic pain (UNP), possible neuropathic pain (PNP), and likely neuropathic pain (LNP), 
respectively. (B) Scatter graph showing relationship between VAS (mm) and painDETECT for the rheumatoid arthritis group. The R2 value shows a positive correlation 
between VAS and painDETECT.
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Figure 2 (A) Box plot graph of the distribution of the mean visual analog scale 
(VAS) according to sex. (B) Box and whiskers plot of the distribution of the mean 
VAS with respect to present pain at the time of questioning compared with worst 
pain experienced (*P,0.05).
with a mean VAS of 77.8±10.3 mm, which was statistically 
significant compared with the unlikely neuropathic pain 
group (P#0.0001). Our results suggest that people with RA 
reporting high pain levels by VAS in the clinic could have 
neuropathic elements to their pain measured by tools such 
as painDETECT.
Discussion
We have found that high levels of pain reporting exist in 
RA in people with fairly well-controlled disease activity 
measured by DAS28. The “disconnect” observed between 
pain reporting and disease activity shows that specific com-
ponents of pain in RA exist that may not be fully captured by 
the VAS. Our data from the painDETECT score showed 
that a large proportion of subjects with RA demonstrated 
likely or probable neuropathic pain features. Neuropathic 
pain classically refers to pain that is arising from the central 
nervous system, and it could be, as demonstrated by our 
study, that people with RA are sensitized to pain very early 
on in their disease. We have shown that despite the use of 
disease-modifying agents for RA, including both oral and 
biologic DMARDs, according to NICE guidelines, pain 
reporting remains high. 
Our data suggest that there may be a noninflammatory or 
neuropathic component that is mediating certain components 
of pain perception in RA. In the group we studied, most 
subjects were on oral DMARD therapy, with the majority 
on at least methotrexate (82%) plus additional disease-
modifying drugs. Of note, although the majority of subjects 
were prescribed oral DMARDs, 54% reported high pain 
levels despite use of oral and biologic therapies. The use of 
analgesic medications in the moderate and severe pain groups 
was the highest.
Clinically, RA is identified with synovitis, which clas-
sically corresponds with inflammation-driven pain. Studies 
have shown that inflammation of the synovium leads to an 
acceleration of prostaglandin and bradykinin production, 
which leads to the activation of thin unmyelinated sensory 
nerves (C fibers) in the synovium.23 Inflammation is pivotal 
in the overall perception of pain in RA. However, several 
studies, including the data herein, suggest that despite suf-
ficient suppression of inflammation, there is still persistent 
pain even with the treatment of anti-inflammatory drugs, 
indicating that other factors mediating pain perception are 
involved in RA.24 It has been proposed that after a period 
of time, arthritic joints expand their total receptive field 
to the surrounding area of normal noninflamed tissue. 
The enhanced response to stimulation of joints that are 
inflamed could be mediated by peripheral sensitization.25 
Additional increased pain responses to noninflamed tissue 
could be generated in the spinal cord, leading to central 
sensitization. Central sensitization is when normal inputs 
begin to produce aberrant feedback due to the excitation of 
the neurons in the central nervous system.26 Recent work 
in RA has shown that features such as anxiety, low mood, 
and depression have an impact on clinical pain reporting 
in RA and can influence brain activation in frontal regions, 
measured by brain  functional  neuroimaging studies.27 More 
recently, Rech et al28 showed that people with RA treated 
with biologic therapies could have early improvements in 
brain pain sensitization, observed by brain functional imag-
ing using blood oxygen level-dependent signals, within 
days of treatment with biologic agents such as certolizumab 
pergol, well before an improved clinical response in the 
joints was observed.
From our results, we have identified that people with RA 
prescribed a combination of biologics and DMARDs had an 
overall high mean VAS score compared with the other groups, 
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known as co-codamol).33 Apart from central and peripheral 
sensitization, pain in RA can be further exacerbated by 
comorbidities, including obesity, fibromyalgia, diabetes mel-
litus, smoking, and secondary osteoarthritis.5 Psychological 
and physiological factors also contribute to the perception 
of pain, which is seen in patients with RA who also suffer 
from depression and anxiety.34 Clinicians could evaluate 
people with RA using painDETECT in addition to current 
tools being used to assess disease activity in the future. If 
they showed evidence of likely neuropathic pain, it could 
be addressed potentially with a trial of analgesics targeted 
at neuropathic pain. Interestingly, of the participants in our 
study who had severe pain, approximately 30% had been 
prescribed amitriptyline.
Potential limitations of our study are that numbers 
of patients were relatively small with 100 participants 
recruited. However, this was a feasibility study to test the 
practicality of using the VAS and painDETECT in a clinical 
setting where many parameters are already being used to 
despite DAS28 scores suggesting good control of  disease 
activity. This finding further suggests that there may be 
additional factors involved in RA pain processing other than 
inflammation alone. Biologics are powerful and expensive 
treatments usually given to patients with high DAS28 (.5.1). 
A reduction in DAS28 of 1.2 points or more is considered 
as guidance for response criteria to biologic therapies and 
also considered as a benchmark for continuing treatment.29 
DMARDs are a group of drugs that are unrelated and used 
in the treatment of RA to slow down the disease progression, 
limiting joint damage and improving function.30 A window 
of opportunity has emerged in RA treatment where earlier 
treatment with DMARDs equates with improved long-term 
outcomes.31,32 DMARDs help primarily to reduce inflamma-
tion and likely inflammatory pain. Together with agents such 
as nonsteroidal anti-inflammatory drugs, they help to limit 
and control the symptoms of RA. Additional analgesic agents 
that were reported to be of high usage in our study included 
paracetamol and codeine (can also be given in combination, 
A Body mass index – BMI score
B
Subscale Mean (SD)
Normal (18.5–24.9) 23.1±1.8
26.2±1.1
30.2±0.3
Overweight (25.0–29.9)
Obese (≥30)
100
M
ea
n
 V
A
S
 (
m
m
) 80 45.2±21.8
Normal
N=61
Overweight
N=37
Obese
N=2
70.1±16.1
****
**
89.0±0.7 Normal (18.5–24.9)
Overweight (25.0–29.9)
Obese (≥30)
60
40
20
0
The data are presented as mean (SD).  Total sample size: 100 participants
Figure 3 (A) Table showing categorization of rheumatoid arthritis group by body mass index (BMI). (B) Bar graph showing the distribution of visual analog scale (VAS) by 
BMI in the rheumatoid arthritis group. Participants were subgrouped by BMI into normal, overweight, and obese. The number (N) of participants within each BMI category 
is given. The mean (standard deviation [SD]) VAS in the groupings described is shown. There were statistically significant differences observed in the overweight and obese 
groups compared with controls (**P,0.01, ****P,0.0001).
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Figure 4 (A) Bar graph showing mean ± standard deviation pain scores for visual analog scale (VAS) and their relationship to use of disease-modifying antirheumatic drug 
(DMARD) therapy in the rheumatoid arthritis group (**P#0.01; ***P#0.001; ****P#0.0001). (B) Bar graph showing the relationship between the mean ± standard deviation 
VAS and painDETECT questionnaire. Participants were grouped into three: unlikely neuropathic pain (UNP), possible neuropathic pain (PNP), and likely neuropathic pain 
(LNP) (**P#0.01; ****P#0.0001).
assess patients, including DAS28, blood tests, and clini-
cal examinations. We asked participants to complete the 
questionnaire, which took an additional 10–15 minutes of 
their appointment, and patients reported that it was user-
friendly and practical within a clinical setting. A further 
limitation is that we did not evaluate mood disorders in 
our study group. There is extensive literature (reviewed by 
Dougados et al35) to suggest that the emotional component 
of pain interferes with the efficacy of treatment. Future work 
is aimed at increasing the sample size, collecting data on 
mood disorders, and assessing test–retest reliability of the 
painDETECT questionnaire in RA in particular.
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Conclusion
In summary, the data from our study suggest that people 
with RA have higher pain sensitivity, with a smaller but 
significant number demonstrating pain sensitization at both 
joint and nonjoint sites using the painDETECT and VAS 
questionnaires. Our data concur with those of McWilliams 
et al,5 who reported high VAS scores in people with RA 
despite active treatment and DAS28 scores suggesting good 
control of disease activity. We suggest that the painDETECT 
score could be a useful tool in the clinic as a measure of 
the “sensitization” element to RA pain. Our findings sug-
gest that implementation of multimodal pain assessment 
tools such as the VAS and painDETECT questionnaires in 
the arthritis clinic setting could open new avenues in the 
assessment and treatment of RA pain in the future.
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